RxDoctor Payments Data

Caroline Ball, MD

Cardiovascular Disease · Maywood, ILNPI 1912343732

Payments from drug & device makers

$603in general payments, 2019–2025

Across 13 payments — averaging $46.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$256
  • Irhythm Technologies, Inc.$124
  • Bridgebio Pharma, Inc.$69
  • Amgen$58
  • Novo Nordisk$47
  • Bayer$25
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$603 in reported general payments places this provider in the 30th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$113,790
Medicare patients
1,020
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban271$281,308
JardianceEmpagliflozin107$136,655
EntrestoSacubitril/Valsartan93$88,462
XareltoRivaroxaban55$76,121
Repatha SureclickEvolocumab79$59,379
WegovySemaglutide20$22,339
MultaqDronedarone Hcl14$18,072
Praluent PenAlirocumab15$10,359
Metoprolol Succinate379$7,575
Bumetanide87$6,054
Atorvastatin Calcium505$5,800
Rosuvastatin Calcium188$4,099
Losartan Potassium275$3,392
Amlodipine Besylate305$3,057
Lisinopril271$2,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy$47$22,33920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →